Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2018 2
2019 1
2021 4
2022 4
2023 6
2025 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
Recent progress in the use of pharmacotherapy for endometrial cancer.
Giudice E, Salutari V, Ricci C, Nero C, Carbone MV, Musacchio L, Ghizzoni V, Perri MT, Camarda F, Tronconi F, Lorusso D, Scambia G. Giudice E, et al. Among authors: perri mt. Expert Opin Pharmacother. 2023 Jan;24(1):83-94. doi: 10.1080/14656566.2022.2106782. Epub 2022 Aug 5. Expert Opin Pharmacother. 2023. PMID: 35912837 Review.
Advanced and recurrent endometrial cancer: State of the art and future perspectives.
Tronconi F, Nero C, Giudice E, Salutari V, Musacchio L, Ricci C, Carbone MV, Ghizzoni V, Perri MT, Camarda F, Gentile M, Berardi R, Scambia G, Lorusso D. Tronconi F, et al. Among authors: perri mt. Crit Rev Oncol Hematol. 2022 Dec;180:103851. doi: 10.1016/j.critrevonc.2022.103851. Epub 2022 Oct 17. Crit Rev Oncol Hematol. 2022. PMID: 36257537 Review.
Benefit from maintenance with PARP inhibitor in newly diagnosed ovarian cancer according to BRCA1/2 mutation type and site: a multicenter real-world study.
Marchetti C, Fagotti A, Fruscio R, Cassani C, Incorvaia L, Perri MT, Sassu CM, Camnasio CA, Giudice E, Minucci A, Seca M, Arbustini E, Vertechy L, De Bonis M, Boccia SM, Giannarelli D, Salutari V, Distefano M, Ferrandina MG, Nero C, Musacchio L, Russo A, Scambia G, Lorusso D. Marchetti C, et al. Among authors: perri mt. ESMO Open. 2025 Apr;10(4):104533. doi: 10.1016/j.esmoop.2025.104533. Epub 2025 Apr 1. ESMO Open. 2025. PMID: 40174507 Free PMC article.
Management of early-stage ovarian cancer: Open questions and debated issues.
Salutari V, Giudice E, Rapisarda E, Pavone M, Ghizzoni V, Perri MT, Boccia SM, Lardino S, Gallotta V, Fagotti A, Scambia G, Lorusso D. Salutari V, et al. Among authors: perri mt. Crit Rev Oncol Hematol. 2025 Jun;210:104704. doi: 10.1016/j.critrevonc.2025.104704. Epub 2025 Mar 17. Crit Rev Oncol Hematol. 2025. PMID: 40107434 Review.
Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.
Pignata S, Scambia G, Schettino C, Arenare L, Pisano C, Lombardi D, De Giorgi U, Andreetta C, Cinieri S, De Angelis C, Priolo D, Casanova C, Rosati M, Greco F, Zafarana E, Schiavetto I, Mammoliti S, Cecere SC, Salutari V, Scalone S, Farolfi A, Di Napoli M, Lorusso D, Gargiulo P, Califano D, Russo D, Spina A, De Cecio R, Chiodini P, Perrone F; MITO investigators. Pignata S, et al. Lancet Oncol. 2023 Mar;24(3):286-296. doi: 10.1016/S1470-2045(23)00016-5. Epub 2023 Feb 14. Lancet Oncol. 2023. PMID: 37052965 Clinical Trial.
24 results